Georgia Avgerinou

Learn More
BACKGROUND Psoriasis is a chronic, systemic, inflammatory disease. Inflammatory markers are used in clinical practice to detect acute inflammation, and as markers of treatment response. Etanercept blocks tumour necrosis factor (TNF)-α, which plays a central role in the psoriatic inflammation process. AIM To reveal any possible association between disease(More)
BACKGROUND Psoriasis is an immune cell-mediated disease in which cytokines play an important role. Studies have been performed to explore the relationship between the disease and cytokine blood levels with a view to finding a biomarker for monitoring disease severity/activity and treatment efficacy. AIM To investigate the levels of transforming growth(More)
BACKGROUND There is evidence that a T-helper (Th) 2 cytokine pattern dominates in the peripheral blood as well as in tissue of patients with Sézary syndrome (SS), and that the malignant clone is of Th2 phenotype. However, there are conflicting studies on the cytokine pattern in the peripheral blood in different stages of cutaneous T-cell lymphoma (CTCL). (More)
UNLABELLED BACKGROUND Topical immunotherapy with diphencyprone (DPCP) is considered the most effective treatment of alopecia areata (AA). OBJECTIVE To assess the efficacy of DPCP in the treatment of extensive or long-lasting AA in Greek patients. METHODS Sixty-four patients with extensive and/or long-lasting AA were sensitized with 2% diphencyprone.(More)
BACKGROUND Venom immunotherapy (VIT) is the only effective treatment for hymenoptera hypersensitivity, but conventional protocols require a few weeks. OBJECTIVE We present the safety of a 3-day "rush" protocol that requires only 7 injections and 255 mgr cumulative dose before the 100 microg maintenance dose. METHODS Forty-nine patients (33 males, 16(More)
AIMS To assess the efficacy and safety of rituximab in refractory pemphigus and the possible benefit of an additional prophylactic infusion at 6 months. METHODS Seventeen patients with pemphigus vulgaris, 1 with pemphigus foliaceus and 1 with pemphigus vegetans were treated with 4 weekly infusions of rituximab (375 mg/m(2)). Nine patients received an(More)
BACKGROUND Use of biological agents has been shown to be an efficacious approach in psoriasis, when traditional treatments fail. However, there are limited data on the effectiveness and safety of switching from one biological agent to another. OBJECTIVES We aimed to evaluate the effectiveness and safety of etanercept as a sequential treatment in patients(More)
Lupus erythematosus-like syndromes have been reported as an adverse effect of anti-tumour necrosis factor-alpha therapy. We report the case of a patient with rheumatoid arthritis who developed a discoid lupus erythematosus-like eruption after treatment with infliximab. The rash consisted of diffuse scaly erythematous plaques on the face, trunk and(More)